Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash & Equivalents for 9 consecutive years, with $205.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 17.36% to $205.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $205.3 million through Dec 2025, up 17.36% year-over-year, with the annual reading at $205.3 million for FY2025, 17.36% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $205.3 million at Denali Therapeutics, up from $91.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $485.7 million in Q2 2021, with the low at $56.9 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $178.8 million, with a median of $136.6 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 254.04% in 2021, then crashed 75.89% in 2022.
  • Over 5 years, Cash & Equivalents stood at $293.5 million in 2021, then dropped by 25.7% to $218.0 million in 2022, then tumbled by 41.71% to $127.1 million in 2023, then soared by 37.65% to $175.0 million in 2024, then rose by 17.36% to $205.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $205.3 million, $91.0 million, and $141.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.